Skip to content
value.today

Accelerate Diagnostics, Inc.: valuation

What the market value assumes, and what the company's own statements and its peers' prices would put it at. Every assumption is yours to change.

Cash-flow value

Free cash flow over the last three years averaged below zero, so a cash-flow value cannot be worked out.

Price to salesPrice to sales of Diagnostics and Research: $28 M to $94 M, median $63 M$0 M$25 M$50 M$76 M$101 M

Your own DCF model

A full discounted-cash-flow model of Accelerate Diagnostics, Inc., started from its filings: revenue growth and margins year by year, bear, base and bull cases, the WACC and its parts, sensitivity tables and a value per share against the dated market price. Save it, share it with your team or by a read-only link.

Open the DCF model

Against the industry Diagnostics and Research

Multiples of its companies with a market value at most 60 days old, times Accelerate Diagnostics, Inc.'s own figures of FY2024.

Values from the peers' multiples
MultiplePeers (25th / median / 75th)The companyApplied toValue (25th to 75th)Companies
Price to sales2.4× / 5.4× / 8.0×—revenue $12 M$28 M to $94 M37

Peers' multiples from the distributions by industry; the company's figures from its statements below. A multiple says what similar companies cost, not what this one is worth.

Against its own history

Accelerate Diagnostics, Inc.'s multiples at each month end with a market cap on file, Jan 2020 to Apr 2025, each against its own median.

Price to sales

1.1×

Now below its median of 4.1×, in the bottom quarter of its range; range 1.1× to 166.0× over 12 months.

0×41×83×124×166×202020212022202320242025Price to sales 1×Median 4×

as of Apr 25, 2025. Market caps: the dated values on file since 2020, and in between the SEC's fails-to-deliver closing price times the share count on the latest 10-K or 10-Q cover. Each month divides by the last twelve months' results that had been published by then (a quarter 45 days after it ended, a fiscal year 60 days after), so the past is not read with figures that came out later; months with a loss give no P/E. Newest month: Apr 25, 2025.

The statements it starts from

USD millions at each year's exchange rate; free cash flow = cash from operations less capital spending.

Figures from the annual statements
Fiscal yearRevenueNet incomeCash from operationsCapital spendingFree cash flowNet debtSource
FY2024to Dec 31, 2024$12 M$-50 M$-24 M$1 M$-25 M—SEC annual report (10-K, 20-F)
FY2023to Dec 31, 2023$12 M$-62 M$-40 M$1 M$-41 M—SEC annual report (10-K, 20-F)
FY2022to Dec 31, 2022$13 M$-62 M$-49 M$1 M$-49 M—SEC annual report (10-K, 20-F)
FY2021to Dec 31, 2021$12 M$-78 M$-47 M$1 M$-48 M$-40 MSEC annual report (10-K, 20-F)
FY2020to Dec 31, 2020$11 M$-78 M$-50 M$1 M$-52 M$-31 MSEC annual report (10-K, 20-F)
FY2019to Dec 31, 2019$9 M$-84 M$-65 M$0 M$-65 M$-61 MSEC annual report (10-K, 20-F)

Each figure as filed; the full statements with every line and its filing are on the company page. Market value not on file.

How it is worked out: the cash-flow value is free cash flow grown at the first-stage rate for the years chosen, then at the long-run rate for ever, each year discounted at the risk-free rate plus the equity risk premium, less net debt. What the price assumes is the first-stage growth that makes that value equal today's market value. The starting cash flow, growth and net debt come from the statements; the risk-free rate from the US Treasury; the premium and the long-run growth are assumptions and are labelled so. This is arithmetic on reported figures, not advice.